Business Description
Founded over two decades ago and headquartered in Sydney, Biotron Limited works to bring new treatments for viral illnesses to market. Its primary focus is a drug called BIT225, which targets a range of serious infections including HIV-1, hepatitis B and C, COVID-19, influenza, and dengue fever.
